

EFSD

European Foundation for the Study of Diabetes

Report - 2012

CONTENTS	PAGE
Introduction	1
Grant Programmes 2012	2
EFSD Clinical Research Grants in the Field of Diabetes	3
EFSD Research Programme in Diabetes and Cancer	4
EFSD New Horizons Collaborative Research Initiative	5
EFSD European Diabetes Research Programme in Patient Education supported by an educational research grant from AstraZeneca/BMS	6
EFSD/Boehringer Ingelheim European Diabetes Research Programmes	7
EFSD/Chinese Diabetes Society/Lilly Collaborative Diabetes Research Programme	8
EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research	9
EFSD/Janssen Programme for the Study of the Role of the Kidney in Diabetes	10
EFSD/Lilly European Diabetes Research Programme	11
EFSD/Lilly Mental Health and Diabetes Programme	12
EFSD/Merck Sharp & Dohme (MSD) European Research Programme on Novel Therapies for Type 2 Diabetes	13
EFSD/Novo Nordisk Partnership for Diabetes Research in Europe	14
EFSD/Sanofi European Research Programme in Micro- and Macrovascular Complications of Diabetes	15
Fellowship Programmes 2012	16
EFSD Albert Renold Travel Fellowships supported by Merck Sharp and Dohme (MSD)	17
EFSD Chinese Diabetes Society/Lilly Research Fellowships	19
EFSD/Lilly Research Fellowships	20
EFSD/Janssen Rising Star Fellowships	21
EFSD/Japanese Diabetes Society Reciprocal Travel Fellowships	22
EFSD/JDRF/Novo Nordisk Research Fellowships	23
EFSD/Sanofi Clinical Research Fellowships	24

New Programmes for 2013	25
EFSD New Horizons Clinical Research Training Fellowships	26
EFSD/Novartis European Research Programme in Microvascular Complications of Diabetes	27

*Note: the above relates solely to programmes which have been officially agreed
at the time of writing this report.*

EFSD Review Committee Members	28
EFSD Executive Committee and Administration	29

In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

[EFSD and its partners bring over Euro 88 Million to European diabetes research](#)

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over **Euro 88 Million** to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: www.EuropeanDiabetesFoundation.org. An RFA (request for applications) for each Programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.

GRANT

PROGRAMMES

2012

Clinical Research Grants in the Field of Diabetes

Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity. The proposed investigation must be carried out in humans; although in vitro and ex vivo studies are acceptable, the in vivo component must clearly be the more relevant part of the project.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Patrick Schrauwen: Maastricht University Medical Centre - The Netherlands
Jørgen Wojtaszewski: University of Copenhagen - Denmark

Research Programme in Diabetes and Cancer

Plan

The EFSD Research Programme in Diabetes and Cancer was established in order to stimulate and accelerate European research aimed at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer. The role of diabetes therapy including molecular mechanisms is also of interest, and applications for projects carried out in collaboration between diabetes and cancer research institutions are especially welcome.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gabriela da Silva Xavier: Imperial College London - UK

Rachel Dankner: Tel Aviv University - Israel

Nabil Djouder: Spanish National Research Centre - Spain

Soffia Gudbjörnsdóttir: University of Gothenburg – Sweden

Mario Pende: Université Paris Descartes – France

Tami Rubinek: Sheba Medical Center - Israel

Haim Werner: Tel Aviv University - Israel

New Horizons Collaborative Research Initiative

Plan

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed. The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative

This Programme therefore aims to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Petr Bouček: Diabetes Centre IKEM - Prague, Czech Republic *collaborating with Claudia Sommer from University Hospital Würzburg - Germany*
Jan Klimas: Comenius University Bratislava – Slovakia *collaborating with Peter Ochodnický from University of Amsterdam - The Netherlands*
Laszlo Koranyi: Heart Centre Foundation - Balatonfüred, Hungary *collaborating with Leif Groop from Malmö University Hospital – Sweden*
Boris Mankovsky: National Medical Academy - Kiev, Ukraine *collaborating with Geert-Jan Biessels from Utrecht Medical Center – The Netherlands*
Andres Metspalu: University of Tartu – Estonia *collaborating with Mika Ala-Korpela from University of Oulu - Finland*
Tomas Venckunas: Lithuanian Academy of Physical Education – Kaunas, Lithuania *collaborating with Aivaras Ratkevicius from Aberdeen University - UK*

EFSD

European Diabetes Research Programme in Patient Education

supported by an educational research grant from
AstraZeneca/BMS

Background

The AstraZeneca/Bristol-Myers Squibb diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

Plan

This Programme supports research into the clinical and medical evaluation of patient-related outcomes in relation to the type 2 diabetes chronic condition and the benefits of its treatment and management and the potential impact of educational and disease management programmes, focusing on holistic approaches to patients with type 2 diabetes, patient engagement and better understanding of the complex physiological and behavioural aspects of the disease.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Apostolos Tsapas: Aristotle University - Thessaloniki, Greece

EFSD and Boehringer Ingelheim

European Diabetes Research Programmes

Background

Boehringer Ingelheim is a global group of companies that seek to improve the health and well being of people and animals through being a part of an independent, innovative, research and development driven company.

Plan

In order to encourage new projects aimed at advancing current knowledge in this domain, EFSD and Boehringer Ingelheim have established a new partnership called the EFSD/Boehringer Ingelheim European Diabetes Research Programmes. These Programmes consist of two elements, each with a different focus:

Basic Research Programme: *Regulation of Secretion and Function of Non-Insulin Peptides from the Endocrine Pancreas*

Applications dealing with research into the role, function and mechanism of non-beta cells are especially, but not exclusively, welcome.

Clinical Research Programme: *Mechanisms Relating Renal Dysfunction to Cardiovascular Disease in Type 2 Diabetes*

Projects investigating novel biomarkers or the translation of experimental hypotheses and clinical results are especially, but not exclusively, welcome.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Basic Research Programme:

Charna Dibner: University Hospital of Geneva – Switzerland

Peter Flatt: University of Ulster - Coleraine, UK

Patrick Gilon: Catholic University of Louvain - Brussels, Belgium

Ivan Quesada: Miguel Hernandez University - Elche, Spain

Clinical Research Programme:

Ariela Benigni: Mario Negri Institute, Italy

Nikolaus Marx: University Hospital Aachen - Germany

EFSD and The Chinese Diabetes Society (CDS) and Lilly

Background

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Lilly has for more than 85 years been a worldwide leader in diabetes care. Based in Indianapolis, USA Lilly introduced the world's first commercial insulin in 1923 and remains at the forefront of pharmaceutical and delivery-device innovation to manage diabetes.

Plan

This partnership targets collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Wei He: Shenyang He Eye Hospital –China *collaborating with Bart M ter Haar Romenji - Maastricht University Eye Hospital*

Luan Shu: Jinangsu Academy of Chinese Medicine – China *collaborating with Kathrin Maedler - University of Bremen*

Huiguang Tian: Tianjin Women's & Children's Health Centre – China *collaborating with Jaako Tuomilehto - University of Helsinki*

Zhiming Zhu: Daping Hospital –China *collaborating with Martin Tepel, University of Southern Denmark*

EFSD and JDRF and Novo Nordisk

European Programme in Type 1 Diabetes Research

Background

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Per-Ola Carlsson: Uppsala University - Sweden
Constanza Emanuelli: University of Bristol - UK
Cecile Julier: University Paris Diderot – France
Henrik Bindsbøl Mortensen: Herlev Hospital - Denmark
Pau Serra: IDIBAPS - Barcelona, Spain

Programme for the Study of the Role of the Kidney in Diabetes

Background

Janssen represents the pharmaceutical companies of Johnson and Johnson, one of the leading healthcare companies in the world. Janssen develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world, with metabolic diseases as a key area of scientific interest

Plan

This Programme is intended to stimulate and accelerate European research aimed at understanding the role of the kidney in diabetes, with special emphasis on the role of the renal glucose threshold (RGT) as an underlying pathophysiologic mechanism in type 2 diabetes. Both basic and clinical research in this scientific area will be supported.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Ivonne Loeffler: University Hospital – Jena, Germany

European Diabetes Research Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund, which was launched in 2003. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Massimo Federici: University of Rome - Italy

Philippe Gual: Archimed University - Nice, France

Eric Kalkhoven: University Medical Center - Utrecht, The Netherlands

Nils Lycke: University of Gothenburg - Sweden

Susanne Mandrup: University of Southern Denmark - Odense, Denmark

Esther Phielix: Maastricht University Medical Centre - The Netherlands

Patrik Rorsman: University of Oxford - UK

Vera Schrauwen-Hinderling: Maastricht University Medical Centre - The Netherlands

Emmanuel Van Obberghen: University of Nice - France

Mental Health and Diabetes Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

This Programme is aimed at clinical investigations into improved care of patients with diabetes and mental diseases including all forms of depression, schizophrenia and Alzheimer's. Special emphasis should be given to improving the co-operation between psychiatric and diabetes care.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Marijke Bremmer: VUMC - Amsterdam, The Netherlands

EFSD and Merck Sharp & Dohme (MSD)

European Research Programme on Novel Therapies for Type 2 Diabetes

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

This Programme is intended to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Juergen Eckel: German Diabetes Center - Duesseldorf, Germany

Sander Kersten: Wageningen University - The Netherlands

Filip Knop: University of Copenhagen – Denmark

Nils Wierup: University of Lund – Sweden

Sagen Zac-Varghese: Imperial College London - UK

EFSD and Novo Nordisk

Partnership for Diabetes Research in Europe

Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

Plan

This Programme will accept applications from all fields of diabetes research, including both basic and clinical research.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Pontus Boström: Karolinska Institute - Stockholm, Sweden
Joan Guinovart: Institute for Research in Biomedicine - Barcelona, Spain
Olle Korsgren: Uppsala University Hospital - Sweden
Margit Mahlapuu: University of Gothenburg - Sweden
Romano Regazzi: University of Lausanne - Switzerland
Solomon Tesfaye: Royal Hallamshire Hospital - Sheffield, UK
Erik Toonen: Radboud University - Nijmegen, The Netherlands

EFSD and Sanofi

European Research Programme in Micro- and Macrovascular Complications of Diabetes

Background

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes, aiming to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes, strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions.

Awards in 2012

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gabriella Gruden: University of Turin - Italy
John Pernow: Karolinska Institute - Stockholm, Sweden
Åke Sjöholm – Karolinska Institute – Stockholm, Sweden
Thomas Thum: Medical School Hanover - Germany

**FELLOWSHIP
PROGRAMMES
2012**

Albert Renold Fellowships Supported by an unrestricted educational grant from **Merck Sharp & Dohme (MSD)**

Albert Renold Fellowships, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months. Albert Renold Fellowships are available throughout the year.

In 2012 the following Fellowships were awarded:

Teresa Mezza: visiting Joslin Diabetes Center - Boston, USA
Asfaneh Morteza: visiting University Hospital - Zurich, Switzerland
Ana Tellechea: visiting Havard Medical School - Boston, USA
Cecilia Rodriguez: visiting San Carlos Clinical Hospital - Madrid, Spain
Salvatore Calanna: visiting University of Copenhagen – Denmark
Cecilia Nigro: visiting National Institute of Diabetes - Maryland, USA
Roksana Pirzgalska: visiting University of Coimbra – Portugal
Yeray Brito Casillas: visiting Royal Veterinary College – UK
Thomas Reinbothe: visiting Stamford University – USA
Rebecca Simmons: visiting University of Arhus – Denmark
Pär Larsson: visiting University of Tampere – Finland
Milena Cardenas Chavez: visiting Hospital Clinic San Carlos - Madrid, Spain
Tamar Kakhniashvili: visiting King's College London – UK
Jenifer Goncalves: visiting University of Coimbra – Portugal
Simeon Pierre Choukem: visiting University of Oxford – UK
Attilio Pingatore: visiting University of Dresden – Germany
Heidi Ainge: visiting University of Copenhagen – Denmark
Eva Garcia Escobar: visiting University of Reading – UK
Elena Mannino: visiting University of Miami - Florida, USA
Tinatin Goginashvili: visiting Kings College London – UK
Roksana Pirzgalska: visiting University of Porto – Portugal
Sara Garcia Serrano: visiting University of Miami - Florida, USA
Rosa Ramirez-Vela: visiting San Carlos Hospital - Madrid, Spain
Katrien Gaens: visiting University of Heidelberg – Germany
Leticia Roma: visiting Catholic University of Louvain - Brussels, Belgium
Fátima Martins: visiting University of Santiago de Compostela – Spain
Conn Hastings: visiting Harvard University – MA, USA
Stefan Pilz: visiting VU Medical Center – The Netherlands
Sandra Weimer: visiting Joslin Diabetes Centre – Boston, USA
Simone Sep: visiting University of Pisa – Italy
Oulwatosin Kayode: visiting Churchill Hospital – Oxford, UK
Sebastian Schmeisser: visiting University of Crete – Greece
Dennis Dahlmans: visiting Federal Polytechnic of Lausanne – Switzerland
Susanne Baars: visiting Harvard University – MA, USA
Ada Pesapone: visiting Harvard University – MA, USA

Joanna Gaspar: visiting Harvard Medical School – MA, USA
Ivana Nikolic: visiting Uppsala University – Sweden
Thais Pentinat Pelegrin: visiting Groningen University – The Netherlands
Eled Shemesh: visiting Leipzig University – Germany
Ewa Gurgul-Convey: visiting Jagellonian University – Poland
José Francisco López Acosta: visiting Mount Sinai School of Medicine – NY, USA
Martin Picard: visiting University of Copenhagen – Denmark
Mirjam Langeveld: visiting University of Cambridge – UK
Rocky Strollo: visiting Queen Mary University – London, UK
Amelia Fuhrmann: visiting University of Coimbra - Portugal

EFSD
and
The Chinese Diabetes Society (CDS)
and
Lilly

Research Fellowships

The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from young investigators from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

In 2012 the following fellowships were awarded:

Yufei Xiang: Central South University - China, collaborating with
Richard Leslie, University of London



Research Fellowships

The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships form part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under "EFSD/Lilly Diabetes Research Programme".

In 2012 the following Fellowships were awarded:

Lisa Berglund: Lund University - Malmö, Sweden
Maarten Brom: Radboud University - Nijmegen, The Netherlands
Paul Caton: Queen Mary University - London, UK
Marc Claret: IDIBAPS - Barcelona, Spain
Jonathan Esguerra: Lund University - Malmö, Sweden
Bruno Guigas: Leiden University Medical Center - The Netherlands
Laura Herrero: University of Barcelona - Spain
Shahram Hedjazifar: Lundberg Laboratory for Diabetes Research - Göteborg, Sweden
Philippe Klee: University Hospital of Geneva – Switzerland
Anna Motterle: University of Lausanne – Switzerland
Joris Robben: Radboud University – Nijmegen, The Netherlands
Tamás Röszer: Spanish National Cardiovascular Research Centre - Madrid, Spain

EFSD and Janssen

Rising Star Fellowships

The Rising Star Symposium aims to identify promising and innovative young researchers who are developing their research activities in Europe. Selected candidates will have the opportunity to present an overview of their past and ongoing research activities during a multidisciplinary research symposium at this year's EASD Annual Meeting. Four candidates will be selected, two in basic research and two in clinical research. The chosen candidates will be invited by EASD to present a lecture (25 minute lecture + 5 minute discussion) and will receive a commemorative diploma. Travel expenses, hotel and registration costs for the recipients will be covered.

Furthermore the award includes a research fellowship payable to the applicant's institution. The objective of the research fellowship is to encourage innovative research in the field of diabetes. Applicants should have demonstrated their ability in the field of diabetes research.

Candidates for the Rising Star Symposium must be paid-up members of EASD and have a PhD, MD or equivalent degree. The candidates must be under the age of 38 on 1 January in the year of the award. Preference will be given to individuals who normally reside in Europe and who have consistently pursued a well defined and innovative research line, leading to several publications in high impact peer reviewed journals.

In 2012 the following Fellowships were awarded:

Amélie Bonnefond: Lille Pasteur Institute - France

Josefine Beulens: Utrecht University - The Netherlands

Laura Herrero: University of Barcelona

Henrike Sell: German Diabetes Center - Duesseldorf, Germany

EFSD and Japan Diabetes Society

Reciprocal Travel Research Fellowships

The objective of the EFSD/JDS Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for Fellowships to carry out a scientific project will be accepted from applicants working in Japan to travel to Europe or its associated countries and also from those working in Europe or its associated countries to travel to Japan. The host institution must be a recognised academic research institution and applicants should have demonstrated their ability in the field of diabetes research.

Fellowship awards will be paid into the account of the recipients' home institution. The scientific project will be three to twelve months in length with some extra time allowed to complete a language course. The budget may include items such as: salaries, travel, sustenance and consumables. The recipients must start the fellowship within 6 months of notification.

Applications may be made by any scientist or clinician who has been working in a postdoctoral position no longer than five years. Each applicant will need to provide a Letter of Support from both the home and the host institution.

In 2012 the following Fellowship was awarded:

Haruhiko Tanaka: University of Tokyo - Japan

EFSD
and
JDRF
and
Novo Nordisk

Research Fellowships

The objective of the EFSD/JDRF/NN Research Fellowships is to support young investigators engaged in research focused on type 1 diabetes and its complications.

Postdoctoral Fellowships will be awarded to individuals already holding a PhD, MD or equivalent degree. Application may be made by any paid-up member of EASD under the age of 38 years on 1 January 2012.

Research Fellowships must be held at a non-profit institution. The present (home) and/or the host institution should be based in Europe or an associated country and any award will be transferred to a European institution account.

In 2012 the following Fellowships were awarded:

Hila Barash: Chaim Sheba Medical Center - Tel Hashomer, Israel

Caroline Brorsson: Glostrup University - Denmark

Smaragda Lamprianou: Geneva University - Switzerland

Ermelindo Leal: University of Coimbra - Portugal



Clinical Investigator Fellowships

The objective of the EFSD/Sanofi Clinical Investigator Fellowships is to encourage innovative clinical investigation and support talented young investigators engaged in diabetes research.

Postgraduate Fellowships will be awarded to individuals already holding a basic medical qualification (MB, BS, MB ChB, MD, etc). Those holding higher degrees are also welcome to apply. All applicants must be paid-up members of EASD under the age of 38 years on 1 January 2012.

Research Fellowships must be held at a non-profit institution. The present (home) and/or the host institution should be based in Europe or an associated country and any award will be transferred to a European institution account.

In 2012 the following Fellowships were awarded:

Gian Paolo Fadini: University of Padova - Italy

Jeroen Hermanides: Academic Medical Centre - Amsterdam, The Netherlands

Hood Thabit: University of Cambridge - UK

NEW PROGRAMMES

2013

New Horizons Clinical Investigator Fellowships

The EFSD New Horizons Fellowships are intended to support inter-regional training and mentorship of European healthcare professionals wishing to undertake clinical research in diabetes.

Applications for Fellowships will be accepted from healthcare professionals working full-time at a non-profit institution in the following countries and proposing to train in clinical diabetes research with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

Fellowships for the purposes of training in clinical research in diabetes for up to 6 months, are available on an independent competitive review basis.

The deadline date for this programme is 1 March 2013.

European Research Programme in Microvascular Complications of Diabetes

Background

Novartis is a world leader in the research and development of products to protect and improve health and well-being. Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz.

Plan

The Programme is intended to stimulate and accelerate European basic and clinical research focusing on microvascular complications of diabetes. Research will be supported through the award of both basic and clinical research grants.

The deadline date for this programme is 15 July 2013.

**Further Programme details and all deadline dates can be found on the
EFSD website:**

www.europeandiabetesfoundation.org

Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2012 partnership programmes:

Allan Flyvbjerg
Andreas Pfeiffer
Andrew Renehan
Angelo Avogaro
Anne Cooke
Antonio Vidal-Puig
Arne Östman
Bernard Thorens
Bo Ahrén
Bo Feldt Rasmussen
Casper Schalkwijk
Christian Widmann
Coen Stehouwer
Dominique Langin
Edwin Gale
Erik Renström
Fatima Bosch
Fiona Gribble
Flemming Pociot
Francesco Beguinot
Frank Snoek
Fredrik Karpe
Guy Rutter
Hannu Juvonen
Hans de Vries
Helen Colhoun
Henrik Birn
Henrike Sell
Ingrid Mühlhauser
Jean-François Tanti
Jussi Pihlajamäki
Kåre Birkeland
Khalida Ismail
Kristian Hanssen

Krzysztof Strojek
Leszek Czapryniak
Luigi Gnudi
Malin Flodström-Tullberg
Marc de Broe
Marc Donath
Massimo Porta
Matthias Blüher
Michael Stumvoll
Nikolaus Marx
Nobuya Inagaki
Norbert Lamiere
Norbert Stefan
Olle Korsgren
Paul Squires
Per-Henrik Groop
Peter Damm
Peter Kempler
Peter Rossing
Pirjo Nuutila
Roberto Mallone
Roy Taylor
Sally Marshall
Shanta Persaud
Simon Heller
Steve Bain
Sudhesh Kumar
Tina Vilsbøll
Torben Hansen
Trond Jenssen
Valeriya Lyssenko
Yannick LeMarchand-Brustel
Yasuo Terauchi
Yehiel Zick

EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:

President: A Boulton - Manchester
Vice President: F Bosch – Barcelona
Vice President: S del Prato - Pisa
Honorary Secretary: M Walker - Newcastle
Honorary Treasurer: M Roden - Dusseldorf
Editor in Chief - *Diabetologia*: J Zierath - Stockholm
Chairman PGEC: C Tack - Nijmegen

Chairman: U Smith - Göteborg
Honorary Chairman: P A Halban - Geneva

Scientific Board: S Amiel – London
F Beguinot – Naples
S del Prato - Pisa
F Bosch - Barcelona
A Boulton - Manchester
E Ferrannini - Pisa
T Pieber – Graz
G Soltész – Pecs
M Stumvoll – Leipzig
C Tack - Nijmegen

Executive Director: V Jörgens - Düsseldorf
Vice Director: M Grüsser - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0 Fax: + 49 211 75 84 69-29

www.EuropeanDiabetesFoundation.org

Email: Foundation@easd.org

Bank Details

Europäische Stiftung für Diabetesforschung – EFSD
Commerz Bank
Breite Strasse 25
40213 Düsseldorf, Germany

Account / Konto: 600 2146 00 Code / BLZ: 300 800 00

SWIFT / BIC: COBADEFFXXX IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number:15.2.1-St.767
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547